BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
More News related to BMRN
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
More News related to Earnings
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reports Q3 EPS of $0.13, 12 cents better than the analyst estimate of $0.01. Revenue for the quarter was $80.8 million, which compares to the estimate of $82 million.
BioMarin lowers FY09 revenue view to $313-$327 million, versus $324.8 million consensus.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
